Sign In
Buy GUTS
$0.760
-0.0297 (-3.76%)
At Close: Jun 03, 2026
Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Increases By 22.6%
02:44am, Tuesday, 17'th Feb 2026
Fractyl Health, Inc. (NASDAQ: GUTS - Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 14,901,084 sh
Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts
03:04pm, Monday, 02'nd Feb 2026
Fractyl Health offers a buy-the-dip opportunity after an overreaction to underwhelming 6-month pilot data for its Revita device. Revita's pivotal Phase 3 obesity trial is well-funded, with topline res
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
11:46am, Friday, 30'th Jan 2026
LOS ANGELES--(BUSINESS WIRE)--Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS.
Pre-Market Stock Futures: Futures are trading lower as we prepare to close out the trading week. What a difference a day can make. After a blockbuster rally on Wednesday, the stock market reversed cou
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
04:16pm, Thursday, 29'th Jan 2026
LOS ANGELES--(BUSINESS WIRE)--Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS.
Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product
01:48pm, Thursday, 29'th Jan 2026
Fractyl Health Inc. (NASDAQ: GUTS) stock plunged on Thursday after the company hinted at a change in its U.S. regulatory strategy for Revita.
Fractyl Health, Inc. (GUTS) Discusses REMAIN-1 Midpoint Cohort Results on Revita for Weight Maintenance After GLP-1 Discontinuation Transcript
Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolera
Fractyl Health, Inc. (NASDAQ:GUTS) Receives $7.40 Consensus Price Target from Brokerages
04:52am, Wednesday, 14'th Jan 2026
Fractyl Health, Inc. (NASDAQ: GUTS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five analysts that are currently covering the firm, MarketBeat reports. One equities rese
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness
07:00am, Tuesday, 06'th Jan 2026
BURLINGTON, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern-breaking approaches t
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
07:00am, Monday, 05'th Jan 2026
Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026 Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission expected in H2 2026 Approxima
Fractyl Health, Inc. (NASDAQ:GUTS) Receives $7.40 Average PT from Analysts
04:27am, Saturday, 20'th Dec 2025
Fractyl Health, Inc. (NASDAQ: GUTS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five ratings firms that are covering the stock, MarketBeat reports. One analyst
BURLINGTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pioneering pattern-breaking a
Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
07:00am, Monday, 01'st Dec 2025
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat ro
